Positive results were found in phase 1 trial of Yunding Xinyao combination therapy for multi-drug-resistant bacterial infection in China.

On September 15th Everest Pharmaceuticals announced the results of a phase 1 clinical trial in China using the taniborbactam joint cephalosporineto treat multiple drug-resistant bacteria (MDR) infections.
the study achieved its main objectives, the results showed that the combined treatment of cephalosporineand taniborbactam had good safety and tolerance among healthy Chinese volunteers, and no racial differences were found in the key pharmacodynamic parameters.
, Yunding Xinyao is currently conducting a critical Phase 3 clinical trial of the Taniborbactam joint cephalosporinefor the treatment of complex urinary tract infections worldwide.
Taniborbactam (VNRX-5133) is a potentially optimal intravenously administered cyclocarbon compound that inhibits both serine and metal beta-endamide enzymes.
Taniborbactam, in association with the fourth-generation cephalosporin antibiotic cephalosporine , showed antibacterial activity against terratin-negative bacteria that obtained multiple resistance (MDR) from the expression of Class A, Class B, Class C and Class D beta-endamidease.
press release, taniborbactam is currently the only one known to be in late clinical development that blocks class B carbon penicillinase.
The challenge of increasing the rate of multidrage-resistant bacterial infections has been challenged in China," said Ms. Zhu Wei, chief medical officer of Yunding Xinyao Infection Field, in response to the positive results of the taniborbactam combination therapy.
The mechanism of the new beta-endamidease inhibitor taniborbactam, used in partnership with cephalosporine , now established standard therapy), has the potential to treat a wider range of multidrore-resistant bacterial infections, particularly those caused by carbon penicillin-resistant Terrane-negative bacteria, thus helping China to meet the unique challenges it faces.
," she added, "We look forward to accelerating the clinical development of cephalosporine -taniborbactam in this important disease area, bringing a potentially best-in-class therapy to patients worldwide."
" Currently, Yunding Xinyao is conducting a critical Phase 3 clinical trial around the world to evaluate the use of cephalosporine -taniborbactam for the treatment of complex urinary tract infections.
the trial was initiated by Ventorx Pharmaceuticals and conducted in partnership with Yunding Xinyao.
Under the exclusive license agreement between Yunding Xinyao and Ventorx Pharmaceutical, Yunding Xinyao has the right to develop and commercialize cephalosporine -taniborbactam in China (including Hong Kong, Macau, Taiwan), Korea, Indonesia, Malaysia, the Philippines, Thailand, Singapore and Vietnam.
Infections caused by Glollath-negative bacteria are becoming increasingly resistant to drugs, and more Gloran-negative pathogens are now resistant to a variety of antibiotics, making infections difficult to treat and increasing patient mortality.
the United States and Europe, nearly 50,000 people have died from multiple drug-resistant infections.
World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC) have made it a top priority to develop new antibiotics to treat bacterial infections resistant to carbon penicillin.
resources: .1 Everest Medicines Announces Top-line Results from Phase 1 Clinical Trial of Taniborbactam in Combin with Cefepime in China. Retrieved Sep 15,2020, from s2, Yunding Xinyao announced the main results of phase 1 clinical trials conducted in China in collaboration withcephalosporine in China. Retrieved Sep 15, 2020, from Cloud Top New Yew Micro.